Literature DB >> 21612379

High-dose chemotherapy with busulfan and cyclophosphamide and autologous stem cell rescue in patients with Hodgkin lymphoma.

Andrew A Lane, Steven L McAfee, Joanne Kennedy, Christine Dube, Eyal C Attar, Karen K Ballen, Bimalangshu R Dey, Thomas R Spitzer, Yi-Bin Chen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21612379      PMCID： PMC3376379          DOI： 10.3109/10428194.2011.572324

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  14 in total

1.  Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.

Authors:  Norbert Schmitz; Beate Pfistner; Michael Sextro; Markus Sieber; Angelo M Carella; Matthias Haenel; Friederike Boissevain; Reinhart Zschaber; Peter Müller; Hartmut Kirchner; Andreas Lohri; Susanne Decker; Bettina Koch; Dirk Hasenclever; Anthony H Goldstone; Volker Diehl
Journal:  Lancet       Date:  2002-06-15       Impact factor: 79.321

2.  Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation--a similar experience.

Authors:  Eric C Santos; Jolynn Sessions; Don Hutcherson; Christopher Flowers; Amelia Langston; Edmund K Waller
Journal:  Biol Blood Marrow Transplant       Date:  2007-06       Impact factor: 5.742

Review 3.  Autologous and allogeneic stem cell transplantation in Hodgkin's lymphoma.

Authors:  Anna Sureda
Journal:  Hematol Oncol Clin North Am       Date:  2007-10       Impact factor: 3.722

4.  Autologous SCT with a dose-reduced BU and CY regimen in older patients with non-Hodgkin's lymphoma.

Authors:  R Z Yusuf; B Dey; B Y Yeap; S McAfee; E Attar; P S Sepe; C Dube; T R Spitzer; K K Ballen
Journal:  Bone Marrow Transplant       Date:  2008-09-15       Impact factor: 5.483

5.  Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial.

Authors:  D C Linch; D Winfield; A H Goldstone; D Moir; B Hancock; A McMillan; R Chopra; D Milligan; G V Hudson
Journal:  Lancet       Date:  1993-04-24       Impact factor: 79.321

6.  Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen.

Authors:  Charu Aggarwal; Sameer Gupta; William P Vaughan; Gene B Saylors; Donna E Salzman; Rhonda O Katz; Amy G Nance; Arabella B Tilden; Matthew H Carabasi
Journal:  Biol Blood Marrow Transplant       Date:  2006-07       Impact factor: 5.742

7.  How I treat relapsed and refractory Hodgkin lymphoma.

Authors:  John Kuruvilla; Armand Keating; Michael Crump
Journal:  Blood       Date:  2011-01-24       Impact factor: 22.113

8.  Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation.

Authors:  Navin Wadehra; Sherif Farag; Brian Bolwell; Patrick Elder; Sam Penza; Matt Kalaycio; Belinda Avalos; Brad Pohlman; Guido Marcucci; Ronald Sobecks; Thomas Lin; Steven Andrèsen; Edward Copelan
Journal:  Biol Blood Marrow Transplant       Date:  2006-12       Impact factor: 5.742

9.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

Review 10.  Busulfan in hematopoietic stem cell transplantation.

Authors:  Stefan O Ciurea; Borje S Andersson
Journal:  Biol Blood Marrow Transplant       Date:  2009-02-12       Impact factor: 5.742
View more
  5 in total

1.  Current status of autologous stem cell transplantation in relapsed and refractory Hodgkin's lymphoma.

Authors:  Anna Colpo; Ephraim Hochberg; Yi-Bin Chen
Journal:  Oncologist       Date:  2011-12-30

2.  Overexpression miR-520a-3p inhibits acute myeloid leukemia progression via targeting MUC1.

Authors:  Xiao-Yu Chen; Xiao-Hua Qin; Xiao-Ling Xie; Cai-Xiang Liao; Dong-Ting Liu; Guo-Wei Li
Journal:  Transl Oncol       Date:  2022-05-29       Impact factor: 4.803

3.  Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.

Authors:  Christopher R Flowers; Luciano J Costa; Marcelo C Pasquini; Jennifer Le-Rademacher; Michael Lill; Tsiporah B Shore; William Vaughan; Michael Craig; Cesar O Freytes; Thomas C Shea; Mitchell E Horwitz; Joseph W Fay; Shin Mineishi; Damiano Rondelli; James Mason; Ira Braunschweig; Weiyun Ai; Rosa F Yeh; Tulio E Rodriguez; Ian Flinn; Terrance Comeau; Andrew M Yeager; Michael A Pulsipher; Isabelle Bence-Bruckler; Pierre Laneuville; Philip Bierman; Andy I Chen; Kazunobu Kato; Yanlin Wang; Cong Xu; Angela J Smith; Edmund K Waller
Journal:  Biol Blood Marrow Transplant       Date:  2016-03-31       Impact factor: 5.742

4.  Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies.

Authors:  Theodoros Karantanos; Ioannis Politikos; Vassiliki A Boussiotis
Journal:  Blood Lymphat Cancer       Date:  2017-05-09

Review 5.  Targeting Leukemia Stem Cell-Niche Dynamics: A New Challenge in AML Treatment.

Authors:  Paolo Bernasconi; Oscar Borsani
Journal:  J Oncol       Date:  2019-08-07       Impact factor: 4.375
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.